10.6084/m9.figshare.12344354.v1
Arnold Lee
Arnold
Lee
Hannah A. Blair
Hannah A.
Blair
Dexamethasone Intracanalicular Insert: A Review in Treating Post-Surgical Ocular Pain and Inflammation
Adis Journals
2020
Adis Drug Evaluation
review
dexamethasone intracanalicular insert
post-surgical ocular pain and inflammation
OTX-13-002
OTX-14-003
OTX-15-003
2020-06-25 21:44:33
Online resource
https://adisjournals.figshare.com/articles/online_resource/Dexamethasone_Intracanalicular_Insert_A_Review_in_Treating_Post-Surgical_Ocular_Pain_and_Inflammation/12344354
<p>Compliance with Ethical Standards</p>
<p> </p>
<p><i>Disclosure</i>: The preparation of this review was
not supported by any external funding.</p>
<p> </p>
<p><i>Conflicts of interest</i>: Arnold Lee and Hannah Blair are salaried employees of Adis International Ltd/Springer Nature, are responsible for the article content and declare no relevant conflicts of interest.</p>
<p> </p>
<p>Additional information about this
Adis Drug Review can be found <a href="http://www.springer.com/gp/adis/products-services/adis-journals-newsletters/adis-drug-reviews">here</a><b></b></p>
<p> </p>
<p>Abstract</p><p><br></p><p>Dextenza<sup>®</sup>, an intracanalicular
insert that is placed into the lower punctal opening of the eye, gradually releases
dexamethasone for up to 30 days to alleviate pain and inflammation associated
with ophthalmic surgery. A significantly higher proportion of patients treated
with the dexamethasone intracanalicular insert than with the placebo insert had
no pain at day 8 (co-primary endpoint, 7 days post-operation) across three pivotal
phase III trials, and the inflammation co-primary endpoint (absence of anterior
chamber cells) at day 14 (13 days post-operation) was met in two of three
trials. Overall, the dexamethasone intracanalicular insert was effective and
generally well tolerated for the treatment of post-surgical ocular pain and
inflammation following cataract surgery. As low patient adherence is an issue
for topical ophthalmic anti-inflammatory medications, the convenience (ease of
insertion, single application with no patient input and typically no removal
required) of the dexamethasone intracanalicular insert makes it a promising
emerging option for the treatment of ocular inflammation and pain following
ophthalmic surgery.</p><p><br></p><p>© Springer Nature Switzerland AG 2020<br></p>